Facilitating access and disease treatment with faster to market solutions for respiratory viral infections
Rivanima Therapeutics offers accessible, safe, and lower-cost outpatient treatment options as a priority in our global efforts to combat COVID-19
Reduction in viral load
Diminished risk of advanced disease
Reduced hospitalization
Short and Ambulatory treatment
Accessible
Reduction in viral load
Reduced hospitalization
Accessible
Diminished risk of advanced disease
Short and Ambulatory treatment
ABOUT US
Company Highlights
Early-stage Biotech Company, incorporated in DE, USA
Operations based in FL, USA and Bogota, Colombia
Developing an early and affordable treatment for COVID-19
Janeth Mora
CEO
PharmD
Dr. Carlos Riveros
Founder - CMO
MD
Carlos R. Olarte
CIPO
B.S.E, J.D.
Juan D. Martinez
Growth & Business Development
J.D.
Founders and management team: +50 years Healthcare/Pharma experience
Sizable billions dollars Market (2022) in COVID-19 for early treatment only
Potential for use as Preventative treatment
Opportunity for usage in other diseases
Rivanima Therapeutics
Early-stage, privately owned Biotech Company
Bringing affordable therapeutic solutions to COVID-19 & developing a portfolio of solutions to address other viral diseases
Our Product
Nebuliv
by Rivanima Therapeutics
Has shown efficacy to reduce viral replication in vitro
However, systemic (oral) delivery of Nebuliv is insufficient to reach required concentrations, and reason why this molecule has not shown adequate efficacy in vivo